메뉴 건너뛰기




Volumn 7, Issue 6, 2005, Pages 244-249

Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy

Author keywords

5 FU; Colorectal cancer; CPT 11; Fluoropyrimidine; Irinotecan

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; IRINOTECAN;

EID: 32944457688     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/BF02710170     Document Type: Article
Times cited : (4)

References (26)
  • 2
    • 0035289220 scopus 로고    scopus 로고
    • Update on chemotherapy for advanced colorectal cancer
    • Haller DG. Update on chemotherapy for advanced colorectal cancer. Oncology (Huntingt). 2001; 15: 11-5.
    • (2001) Oncology (Huntingt) , vol.15 , pp. 11-15
    • Haller, D.G.1
  • 5
    • 0036304427 scopus 로고    scopus 로고
    • Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins
    • García-Carbonero R., Supko JG Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002; 8: 641-61.
    • (2002) Clin Cancer Res. , vol.8 , pp. 641-661
    • García-Carbonero, R.1    Supko, J.G.2
  • 6
    • 0027140524 scopus 로고
    • Phase I and pharmacokinetic trial of weekly CPT-11
    • Rothenberg ML, Kuhn JG, Burris H.A., et al Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993; 11: 2194-204.
    • (1993) J Clin Oncol. , vol.11 , pp. 2194-2204
    • Rothenberg, M.L.1    Kuhn, J.G.2    Burris, H.A.3
  • 7
    • 0028854897 scopus 로고
    • Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
    • Abigerges D, Chabot GG, Armand J.P., Herait P., Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol. 1995; 13: 210-21.
    • (1995) J Clin Oncol. , vol.13 , pp. 210-221
    • Abigerges, D.1    Chabot, G.G.2    Armand, J.P.3    Herait, P.4    Gouyette, A.5    Gandia, D.6
  • 8
    • 0025851286 scopus 로고
    • Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer
    • Negoro S, Fukuoka M, Masuda N., et al Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst. 1991; 83: 1164-8.
    • (1991) J Natl Cancer Inst. , vol.83 , pp. 1164-1168
    • Negoro, S.1    Fukuoka, M.2    Masuda, N.3
  • 9
    • 0035695192 scopus 로고    scopus 로고
    • Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
    • Rothenberg ML, Kuhn JG, Schaaf L.J., et al Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol. 2001; 12: 1631-41.
    • (2001) Ann Oncol. , vol.12 , pp. 1631-1641
    • Rothenberg, M.L.1    Kuhn, J.G.2    Schaaf, L.J.3
  • 10
    • 0034568428 scopus 로고    scopus 로고
    • Chemoprotective and radioprotective effects of amifostine: An update of clinical trials
    • Capizzi RL, Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int J Hematol. 2000; 72: 425-35.
    • (2000) Int J Hematol. , vol.72 , pp. 425-435
    • Capizzi, R.L.1    Oster, W.2
  • 11
    • 0037089642 scopus 로고    scopus 로고
    • Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma
    • Delioukina ML, Prager D, Parson M., Hecht JR, Rosen P, Rosen LS Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer. 2002; 94: 2174-9.
    • (2002) Cancer , vol.94 , pp. 2174-2179
    • Delioukina, M.L.1    Prager, D.2    Parson, M.3    Hecht, J.R.4    Rosen, P.5    Rosen, L.S.6
  • 13
    • 0037540807 scopus 로고    scopus 로고
    • National Cancer Institute MD, Division of Cancer Treatment, National Cancer Institute
    • National Cancer Institute. Guidelines for the reporting of adverse drug reactions. MD, Division of Cancer Treatment, National Cancer Institute; 1999: 1-80.
    • (1999) Guidelines for the Reporting of Adverse Drug Reactions , pp. 1-80
  • 15
    • 0033053920 scopus 로고    scopus 로고
    • Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
    • Van Cutsem E., Cunningham D, Ten Bokkel Huinink WW, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer. 1999; 35: 54-9.
    • (1999) Eur J Cancer , vol.35 , pp. 54-59
    • Van Cutsem, E.1    Cunningham, D.2    Ten Bokkel Huinink, W.W.3
  • 16
    • 84873476033 scopus 로고    scopus 로고
    • Irinotecan (CPT-11) as first-line monotherapy in patients with advanced, metastatic colorectal cancer refractory to 5-fluorouracil adjuvant chemotherapy: A multicenter phase II study
    • Navarro M, Losa F, Manzano H., et al Irinotecan (CPT-11) as first-line monotherapy in patients with advanced, metastatic colorectal cancer refractory to 5-fluorouracil adjuvant chemotherapy: a multicenter phase II study. Rev Oncol. 2002; 4: 385-90.
    • (2002) Rev Oncol. , vol.4 , pp. 385-390
    • Navarro, M.1    Losa, F.2    Manzano, H.3
  • 17
    • 10744226030 scopus 로고    scopus 로고
    • Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): A phase II study
    • Anton A, Aranda E, Carrato A., et al Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. Methods Find Exp Clin Pharmacol. 2003; 25: 639-43.
    • (2003) Methods Find Exp Clin Pharmacol. , vol.25 , pp. 639-643
    • Anton, A.1    Aranda, E.2    Carrato, A.3
  • 18
    • 0034727063 scopus 로고    scopus 로고
    • Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group
    • Saltz LB, Cox JV, Blanke C, et al Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343: 905-14.
    • (2000) N Engl J Med. , vol.343 , pp. 905-914
    • Saltz, L.B.1    Cox, J.V.2    Blanke, C.3
  • 19
    • 0031014627 scopus 로고    scopus 로고
    • Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretre-ated with fluorouracil-based chemotherapy
    • Rougier P, Bugat R, Douillard J.Y., et al Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretre-ated with fluorouracil-based chemotherapy. J Clin Oncol. 1997; 15: 251-60.
    • (1997) J Clin Oncol. , vol.15 , pp. 251-260
    • Rougier, P.1    Bugat, R.2    Douillard, J.Y.3
  • 20
    • 0032585232 scopus 로고    scopus 로고
    • Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
    • Cunningham D, Pyrhonen S, James R.D., et al Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352: 1413-8.
    • (1998) Lancet , vol.352 , pp. 1413-1418
    • Cunningham, D.1    Pyrhonen, S.2    James, R.D.3
  • 21
    • 0032585197 scopus 로고    scopus 로고
    • Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
    • Rougier P, Van Cutsem E, Bajetta E, et al Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998; 352: 1407-12.
    • (1998) Lancet , vol.352 , pp. 1407-1412
    • Rougier, P.1    Van Cutsem, E.2    Bajetta, E.3
  • 22
    • 0033558004 scopus 로고    scopus 로고
    • A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
    • Rothenberg ML, Cox JV, DeVore R.F., et al A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999; 85: 786-95.
    • (1999) Cancer , vol.85 , pp. 786-795
    • Rothenberg, M.L.1    Cox, J.V.2    DeVore, R.F.3
  • 23
    • 0030818926 scopus 로고    scopus 로고
    • Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
    • Pitot HC, Wender DB, O'Connell MJ, et al Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol. 1997; 15: 2910-9.
    • (1997) J Clin Oncol. , vol.15 , pp. 2910-2919
    • Pitot, H.C.1    Wender, D.B.2    O'Connell, M.J.3
  • 24
    • 0345375527 scopus 로고    scopus 로고
    • Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination
    • Tsavaris N, Ziras N, Kosmas C., et al Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. Cancer Chemother Pharmacol. 2003; 52: 514-9.
    • (2003) Cancer Chemother Pharmacol. , vol.52 , pp. 514-519
    • Tsavaris, N.1    Ziras, N.2    Kosmas, C.3
  • 25
    • 0036605387 scopus 로고    scopus 로고
    • Triplet combination with irinotecan plus oxaliplatin plus continuousinfusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial
    • Souglakos J, Mavroudis D, Kakolyris S., et al Triplet combination with irinotecan plus oxaliplatin plus continuousinfusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol. 2002; 20: 2651-7
    • (2002) J Clin Oncol. , vol.20 , pp. 2651-2657
    • Souglakos, J.1    Mavroudis, D.2    Kakolyris, S.3
  • 26
    • 0035990069 scopus 로고    scopus 로고
    • Addition of either irinotecan or methotrexate to bolus 5-fluoruracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: A randomised study by the southern Italy cooperative oncology group
    • Comella P, Crucitta E, De Vita L, et al Addition of either irinotecan or methotrexate to bolus 5-fluoruracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Annals Oncol. 2002; 13: 866-73.
    • (2002) Annals Oncol. , vol.13 , pp. 866-873
    • Comella, P.1    Crucitta, E.2    De Vita, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.